Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065117 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00065117 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 180 participants.
The verdict
NCT00065117, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the Safety, Tolerability and Efficacy of ZD6126 in Combination with Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects with Metastatic Colorectal Cancer.
Interventions
- DRUG Placebo
- DRUG 5-fluorouracil
- DRUG oxaliplatin
- DRUG leucovorin
- DRUG ZD6126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2003-09 |
| Est. Completion | 2004-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00065117
The ClinicalTrials.gov registry entry for NCT00065117 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00065117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00065117 about?
NCT00065117 is a clinical study titled "Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.". The purpose of this study is to assess the Safety, Tolerability and Efficacy of ZD6126 in Combination with Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects with Metastatic Colorectal Cancer.
What is the current status of trial NCT00065117?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2003-09. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00065117?
The interventions under investigation include: Placebo (DRUG), 5-fluorouracil (DRUG), oxaliplatin (DRUG), leucovorin (DRUG), ZD6126 (DRUG).
Who is sponsoring clinical trial NCT00065117?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.